TransMedics Group, Inc. Common Stock (TMDX) — 分析摘要
TransMedics Group, Inc. Common Stock(TMDX)的市值为2.62十亿美元,最近一年的营收同比增长了+37.1%。净利润率为31.4%。当前市盈率为15.2倍。
核心要点
- 营收同比变化+37.1%
- 净利润率31.4%
- 市盈率15.2倍
与ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS板块的其他公司相比,TMDX的营收增长为+37.1%,市盈率为15.2倍。
TransMedics Group, Inc. Common Stock (TMDX)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报,没有触发重大的信用、利润率或趋势红旗。
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
行业
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
员工人数
898
总部
ANDOVER, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。